Drug Trial Radar · NCT06965114
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
Mar 1, 2030
Study completion Mar 1, 2030
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- May 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leukemia (cHCL) that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory) and compares the effect of tovorafenib and rituximab to current standard treatment of cladribine and rituximab in cHCL patients that have not yet received treatment. Tovorafenib blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cladribine damages the cell's deoxyribonucleic acid and may kill cancer cells. It is a type of antimetabolite. Giving tovorafenib in combination with rituximab may be safe and tolerable and more effective than cladribine with rituximab in treating patients with untreated, recurrent or refractory cHCL.
Conditions
- Hairy Cell Leukemia
- Recurrent Hairy Cell Leukemia
- Refractory Hairy Cell Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo blood sample and buccal swab collection
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy and aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy and aspiration
CladribineDrug
Given IV
Computed TomographyProcedure
Undergo CT
RituximabBiological
Given IV
TovorafenibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (Phase 1)Time frame: During cycles 1-3 (cycle length = 28 days)
- Minimal residual disease negative complete remission (MRD [-] CR) rate (Phase 2)Time frame: At completion of tovorafenib plus rituximab treatment versus cladribine plus rituximab
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
NCI - Center for Cancer Research
Bethesda, Maryland · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.